Alice Blue Home
URL copied to clipboard

Trending News

Pharma stock: Gland pharma receives USFDA approval for vasopressin in 5% dextrose RTU injection

Gland Pharma Limited has received USFDA approval for Vasopressin 5% Dextrose Injection RTU vials, including 40-unit and tentative 20-unit approvals, for treating vasodilatory shock in adults.

Introduction

Leading pharmaceutical company receives USFDA approval for Vasopressin 5% Dextrose Injection RTU vials, including 40-unit approval and tentative 20-unit approval, for treating vasodilatory shock in adults, expanding its injectable product portfolio in the U.S. market.

Alice Blue Image

Also Read: Sona BLW Precision: Stock jumps after receiving 3 PLI certifications of EVs

Share price movement of Gland Pharma

On August 26, 2025, Gland Pharma Ltd opened at ₹1964.35, up 1.18% from its previous close of ₹1941.95. The stock reached a high of ₹1964.35 and a low of ₹1915.00. By 2:13 PM, it traded at ₹1940.00, a 0.10% decrease, with a market cap of ₹31,962.75 crore.

Gland Pharma Gets USFDA Approval for Vasopressin

Gland Pharma Limited has received USFDA approval for Vasopressin 5% Dextrose Injection USP, 40 Units per 100 mL RTU vials. The company also received tentative approval for 20 Units per 100 mL RTU vials.

The product is bioequivalent and therapeutically equivalent to VASOSTRICT Injection by PH Health. It is indicated to increase blood pressure in adults with vasodilatory shock. US sales of this product were approximately USD 45 million for the year ending June 2025.

Stock performance of Gland Pharma for Period of 1 week, 6 months, and 1 year

Gland Pharma Ltd delivered a -0.18% return over the past week. The stock gained 20.0% in the past six months and 4.68% over the past year.

Alice Blue Image

Also Read: BLS International: Stock jumps 3% after receiving ₹2,055.35 Cr order from UIDAI

Shareholding pattern of Gland Pharma

ParticularsJun 2025Mar 2025Dec 2024
Promoter51.80%51.80%51.80%
FII7.40%6.90%5.00%
DII32.90%33.30%34.80%
Public7.90%8%8.30%

About Gland Pharma

Gland Pharma Limited (NSE: GLAND), established in 1978, is a leading injectable-focused pharmaceutical company with a global presence in 60 countries, specializing in developing, manufacturing, and marketing sterile injectables across various dosage forms and therapies.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs

Q: Why is Gland Pharma Ltd share price going up today?

A: The stock rose after receiving USFDA approval for Vasopressin 5% Dextrose Injection RTU vials, including 40-unit approval and tentative 20-unit approval.

Q: What does Gland Pharma Ltd specialize in?

A: The company specializes in developing, manufacturing, and marketing sterile injectable products, including vials, ampoules, pre-filled syringes, and lyophilized formulations.

Q: What is the market capitalization of Gland Pharma Ltd?

A: Gland Pharma Ltd has a market capitalization of ₹31,962.75 crore as of August 26, 2025.

Submit the form, and get to know how you scored!!!

Gainers & Losers

Read More News

*T&C apply